Benjamin R. Yerxa - 23 Apr 2026 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
27 Apr 2026, 16:28:53 UTC
Prior SEC filing
26 Jan 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Amy Rabourn, by Power of Attorney

Key filing fact

Benjamin R. Yerxa filed Form 4 for Opus Genetics, Inc. (IRD) on 27 Apr 2026.

Key facts

  • This page summarizes Benjamin R. Yerxa's Form 4 filing for Opus Genetics, Inc. (IRD).
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 27 Apr 2026, 16:28.

Change

  • Previous filing in this sequence was filed on 26 Jan 2026.
  • Current net transaction value: -$39,121.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001145910 Primary reporting owner

YERXA BENJAMIN R

Relationship
President, Director
Address
C/O OPUS GENETICS, INC., 8 DAVIS DRIVE, SUITE 220, DURHAM
Signature
/s/ Amy Rabourn, by Power of Attorney
Signature date
27 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IRD transaction

Common Stock

Sale

Transaction value
$39,121
Shares
-7,470
Change %
-1%
Price
$5.24
Shares after
711,535
Date
23 Apr 2026
Ownership
Direct
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares reported on this line were sold automatically on behalf of the Reporting Person, as required by the Company to satisfy tax withholding obligations that arose in connection with a vesting and settlement event from a restricted stock units award. This transaction does not represent a discretionary trade by the Reporting Person.

Footnote F2

The price in column 4 represents the weighted average price. The shares were sold in multiple transactions at prices ranging from $5.2314 to $5.2413, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .